Elevated preoperative plasma level of endoglin has been associated with worse oncologic outcomes in various malignancies. The present large-scale study aimed to determine the predictive and prognostic values of preoperative endoglin with regard to clinicopathologic and survival outcomes in patients treated with radical cystectomy (RC) for nonmetastatic urothelial carcinoma of the bladder (UCB). We prospectively collected preoperative blood samples from 1036 consecutive patients treated with RC for UCB. Logistic and Cox regression analyses were undertaken to assess the correlation of endoglin levels with pathologic and survival outcomes, respectively. The AUC and C-index were used to assess the discrimination. Patients with adverse pathologic features had significantly higher median preoperative endoglin plasma levels than their counterparts. Higher preoperative endoglin level was independently associated with an increased risk for lymph node metastasis, ≥pT3 disease, and nonorgan confined disease (NOCD; all p < 0.001). Plasma endoglin level was also independently associated with cancer-specific and overall survival in both pre- and postoperative models (all p < 0.05), as well as with recurrence-free survival (RFS) in the preoperative model (p < 0.001). The addition of endoglin to the preoperative standard model improved its discrimination for prediction of lymph node metastasis, ≥pT3 disease, NOCD, and RFS (differential increases in C-indices: 10%, 5%, 5.8%, and 4%, respectively). Preoperative plasma endoglin is associated with features of biologically and clinically aggressive UCB as well as survival outcomes. Therefore, it seems to hold the potential of identifying UCB patients who may benefit from intensified therapy in addition to RC such as extended lymphadenectomy or/and preoperative systemic therapy.

Department of Special Surgery Division of Urology Jordan University Hospital The University of Jordan Amman Jordan

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology and Division of Experimental Oncology Urological Research Institute Vita Salute San Raffaele

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology Federal Armed Services Hospital Koblenz Koblenz Germany

Department of Urology King Fahad Specialist Hospital Dammam Saudi Arabia

Department of Urology Luzerner Kantonsspital Lucerne Switzerland

Department of Urology Medical University of Silesia Zabrze Poland

Department of Urology Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama Japan

Department of Urology Semmelweis University Budapest Hungary

Department of Urology The Jikei University School of Medicine Tokyo Japan

Department of Urology University Hospital Zurich Zurich Switzerland

Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany

Department of Urology University of Texas Southwestern Dallas Texas USA

Department of Urology Weill Cornell Medical College New York New York USA

Department of Urology Weill Cornell Medical College New York Presbyterian Hospital New York New York USA

Division of Urology Cancer Prognostics and Health Outcomes Unit University of Montreal Health Center Montreal Canada

Hourani Center for Applied Scientific Research Al Ahliyya Amman University Amman Jordan

Institute for Urology and Reproductive Health Sechenov University Moscow Russia

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Men's Health and Reproductive Health Research Center Shahid Beheshti University of Medical Sciences Tehran Iran

Research Center for Evidence Based Medicine Tabriz University of Medical Sciences Tabriz Iran

Zobrazit více v PubMed

Babjuk M, Burger M, Compérat EM, et al. European Association of Urology Guidelines on non‐muscle‐invasive bladder cancer (TaT1 and carcinoma in situ)–2019 Update. Eur Urol. 2019;76(5):639‐657. 10.1016/j.eururo.2019.08.016 PubMed DOI

Witjes JA, Bruins HM, Cathomas R, et al. EAU Guidelines on Muscle‐invasive and Metastatic Bladder Cancer. Edn. Presented at the EAU Annual Congress Amsterdam 2020. In: Arnhem, The Netherlands: EAU Guidelines Office; 2020.

Witjes JA, Babjuk M, Bellmunt J, et al. EAU‐ESMO consensus statements on the management of advanced and variant bladder cancer—an International Collaborative Multistakeholder Effort†[Formula presented]: under the auspices of the EAU‐ESMO Guidelines Committees. Eur Urol. 2020;77:223‐250. 10.1016/j.eururo.2019.09.035 PubMed DOI

Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A. Tumor markers in prostate cancer I: blood‐based markers. Acta Oncol (Madr). 2011;50 Suppl 1:61‐75. 10.3109/0284186X.2010.542174 PubMed DOI PMC

Karakiewicz PI, Shariat SF, Palapattu GS, et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol. 2006;50:1254‐1260. 10.1016/j.eururo.2006.06.010 PubMed DOI

Kluth LA, Black PC, Bochner BH, et al. Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature. Eur Urol. 2015;68(2):238‐253. 10.1016/j.eururo.2015.01.032 PubMed DOI

Shariat SF, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI. Nomograms for bladder cancer. Eur Urol. 2008;54:41‐53. 10.1016/j.eururo.2008.01.004 PubMed DOI

Shariat SF, Youssef RF, Gupta A, et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol. 2010;183:1744‐1750. 10.1016/j.juro.2010.01.018 PubMed DOI

Soria F, Krabbe LM, Todenhöfer T, et al. Molecular markers in bladder cancer. World J Urol. 2019;37:31‐40. 10.1007/s00345-018-2503-4 PubMed DOI PMC

Byrne RR, Shariat SF, Brown R, et al. E‐cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long‐term follow‐up. J Urol. 2001:1473‐1479. 10.1016/s0022-5347(05)66330-6 PubMed DOI

Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Ki‐67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ‐confined disease. Clin Cancer Res. 2006;12:7369‐7373. 10.1158/1078-0432.CCR-06-1472 PubMed DOI

Putluri N, Shojaie A, Vasu VT, et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res. 2011;71:7376‐7386. 10.1158/0008-5472.CAN-11-1154 PubMed DOI PMC

Rink M, Chun FK, Dahlem R, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol. 2012;61:810‐817. 10.1016/j.eururo.2012.01.017 PubMed DOI

Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer. 2007;109:1106‐1113. 10.1002/cncr.22521 PubMed DOI

Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Cooperative effect of cell‐cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol. 2007;20:445‐459. 10.1038/modpathol.3800757 PubMed DOI

Svatek RS, Shariat SF, Novara G, et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 2011;107:898‐904. 10.1111/j.1464-410X.2010.09628.x PubMed DOI

Schuettfort VM, D'andrea D, Quhal F, et al. A Panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. BJU Int. 2021. 10.1111/bju.15379 PubMed DOI PMC

Laukhtina E, Pradere B, Mori K, et al. Catalog of prognostic tissue‐based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review. Urol Oncol Semin Orig Investig. 2021;39:180‐190. 10.1016/j.urolonc.2020.12.019 PubMed DOI

Shariat SF, Lotan Y, Vickers A, et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol Semin Orig Investig. 2010;28:389‐400. 10.1016/j.urolonc.2010.02.011 PubMed DOI PMC

Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4‐6. 10.1093/jnci/82.1.4 PubMed DOI

Gougos A, Letarte M. Primary structure of endoglin, and RGD‐containing glycoprotein of human endothelial cells. J Biol Chem. 1990;265:8361‐8364. 10.1016/s0021-9258(19)38892-1 PubMed DOI

Takahashi N, Kawanishi‐Tabata R, Haba A, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res. 2001;7(3):524‐532. PubMed

Bozas G, Terpos E, Gika D, Karadimou A, Dimopoulos MA, Bamias A. Prechemotherapy serum levels of CD105, transforming growth factor β2, and vascular endothelial growth factor are associated with prognosis in patients with advanced epithelial ovarian cancer treated with cytoreductive surgery and platinum‐based chemothera. Int J Gynecol Cancer. 2010;20(2):248‐254. 10.1111/IGC.0b013e3181cc25c3 PubMed DOI

Daly S, Kubasiak JC, Rinewalt D, et al. Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. Ann Thorac Surg. 2014;98(6):1968‐1975. 10.1016/j.athoracsur.2014.06.071 PubMed DOI

Karam JA, Svatek RS, Karakiewicz PI, et al. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin Cancer Res. 2008;14(5):1418‐1422. 10.1158/1078-0432.CCR-07-0901 PubMed DOI

Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, Shariat SF. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin Cancer Res. 2008;14(11):3362‐3366. 10.1158/1078-0432.CCR-07-4707 PubMed DOI

Isebaert S, Haustermans K, Van Den Bergh L, et al. Identification and characterization of nodal metastases in prostate cancer patients at high risk for lymph node involvement. Acta Oncol (Madr). 2013;52(7):1336‐1344. 10.3109/0284186X.2013.813070 PubMed DOI

Shariat SF, Andrews B, Kattan MW, Kim JH, Wheeler TM, Slawin KM. Plasma levels of interleukin‐6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 2001;58:1008‐1015. 10.1016/S0090-4295(01)01405-4 PubMed DOI

Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003;61:1140‐1145. 10.1016/S0090-4295(03)00236-X PubMed DOI

Xylinas E, Rink M, Robinson BD, et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer. 2013;49:1889‐1897. 10.1016/j.ejca.2013.02.001 PubMed DOI

Shariat SF, Khoddami SM, Saboorian H, et al. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. J Urol. 2004;171:1122‐1127. 10.1097/01.ju.0000113249.82533.28 PubMed DOI

Rink M, Fajkovic H, Cha EK, et al. Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol. 2012;61:854‐855. 10.1016/j.eururo.2011.12.055 PubMed DOI

D'andrea D, Soria F, Zehetmayer S, et al. Diagnostic accuracy, clinical utility and influence on decision‐making of a methylation urine biomarker test in the surveillance of non‐muscle‐invasive bladder cancer. BJU Int. 2019;123:959‐967. 10.1111/bju.14673 PubMed DOI PMC

Gomceli I, Tez M, Bostanci E, Kemik A, Demiriz B, Akoglu M. Prognostic significance of the preoperative serum levels of soluble form of endoglin in gastric cancer patients. Bratisl Lek List. 2013;114(10):566‐568. 10.4149/bll_2013_119 PubMed DOI

Gomceli I, Tezz M, Bostanci EB, Turhan N, Kemik AS, Akoglu M. Preoperative serum levels of soluble endoglin for prediction of recurrence in stage III colorectal cancer patients. Acta Medica (Hradec Kralove). 2012;55(2):74‐77. 10.14712/18059694.2015.58 PubMed DOI

Li C, Guo B, Wilson PB, et al. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer. 2000;89:122‐126. 10.1002/(sici)1097-0215(20000320)89:2<122::aid-ijc4>3.0.co;2-m PubMed DOI

Tosun H, Demirtaş A, Sönmez G, Tombul ŞT, Akalın H, Özkul Y. Can the expression level of PIWIL 2 gene be a serum marker for prostate cancer? A single‐center prospective study. Turkish J Urol. 2019;45(Supp. 1):S22‐S25. 10.5152/tud.2019.46416 PubMed DOI PMC

Sonmez G, Demirtas T, Tombul ST, Akgun H, Demirtas A. Diagnostic efficiency of systemic immune‐inflammation index in fusion prostate biopsy. Actas Urol Esp. 2021;45(5):359‐365. 10.1016/j.acuro.2020.08.015 PubMed DOI

Santos L, Costa C, Pereira S, et al. Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. Ann Oncol. 2003;14(9):1419‐1424. 10.1093/annonc/mdg377 PubMed DOI

Rosen LS, Hurwitz HI, Wong MK, et al. A phase I first‐in‐human study of TRC105 (Anti‐Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res. 2012;18(17):4820‐4829. 10.1158/1078-0432.CCR-12-0098 PubMed DOI PMC

Kopczyńska E, Dancewicz M, Kowalewski J, et al. Influence of surgical resection on plasma endoglin (CD105) level in non‐small cell lung cancer patients. Exp Oncol. 2012;34(1):53‐56. PubMed

Rink M, Lee DJ, Kent M, et al. Predictors of cancer‐specific mortality after disease recurrence following radical cystectomy. BJU Int. 2013;111:30‐36. 10.1111/j.1464-410X.2012.11433.x PubMed DOI

Blood-Based Biomarkers as Prognostic Factors of Recurrent Disease after Radical Cystectomy: A Systematic Review and Meta-Analysis